Daily
250 words
7/10
Rating

25 July 2026

Qdenga dengue vaccine approval

The approval of Qdenga, India's first dengue vaccine, is a significant development in public health policy and medical technology that directly impacts national disease control strategies.

1 min read Day 2 of 5 2 questions 1 prelims

Notes

  • CDSCO has granted approval for Qdenga, India's first dengue vaccine, developed by Japan-based Takeda.
  • Qdenga has received WHO prequalification and is licensed in over 40 countries.
  • Dengue is caused by four antigenically distinct serotypes; effective vaccines must induce immunity against all four to avoid antibody-dependent enhancement.
  • Unlike the earlier Dengvaxia, Qdenga does not require screening for prior dengue infection before administration.
  • Qdenga requires a two-dose regimen administered three months apart.
  • Efficacy varies by serotype: highest protection against DENV-2, followed by DENV-1, with uncertainty regarding DENV-3 and DENV-4 in seronegative individuals.
  • Rising prevalence of DENV-3 in India poses a potential risk to vaccine efficacy if the serotype dominates during monsoon seasons.
  • Challenges for rollout include ensuring the second dose is administered to mobile populations and managing high costs through tiered pricing negotiations.
  • The TIDES trial indicated concerns regarding 'negative efficacy' against DENV-3-related hospitalisation among seronegative children.

Part of a longer story

This is day 2 of 5 in Approval of Qdenga dengue vaccine in India, which has been running since 21 July 2026. Reading it whole is usually worth more than reading today alone — the exam asks how something developed.

Questions

  1. Discuss the scientific challenges associated with developing an effective vaccine for dengue fever, particularly concerning the phenomenon of antibody-dependent enhancement. 150 words
    Attempt this — 150 words in 8 min
    0 / 150 words 8:00
  2. The approval of the Qdenga vaccine marks a significant milestone in India's public health response to dengue. Critically analyze the operational and epidemiological challenges that must be addressed to ensure an effective national rollout of this vaccine. 250 words
    Attempt this — 250 words in 11 min
    0 / 250 words 11:00

Prelims

  1. Which of the following statements regarding the Qdenga dengue vaccine is correct?

Syllabus

Topics

Sources

250words.in · https://250words.in/daily/2026-07-25/qdenga-dengue-vaccine-approval